Navigation Links
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Date:10/23/2007

SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced preclinical data presented at the 19th annual AACR-NCI-EORTC Symposium show its bis-platinate drug candidates, CT-47613 and CT-47609, kill tumors refractory to currently marketed platinum agents carboplatin, cisplatin and oxaliplatin. These compounds could enter human clinical trials in late 2008.

"Bis-platinates represent a promising new class of platinum-based chemotherapy drugs with a potential broad spectrum of anti-tumor activity. Anti-cancer drugs containing platinum are a cornerstone therapy for a wide range of tumor types including ovarian, testicular, colorectal, head and neck, and lung cancer," said Jack W. Singer, M.D., Chief Medical Officer of CTI. "These bis-platinates, unlike the currently approved platinum compounds, contain two platinum atoms and work by binding to and damaging both strands of DNA making it much more difficult for cancer cells to repair the damage. The preclinical studies presented at this meeting suggest these compounds are substantially more active than the existing monoplatinates -- especially against platinum-resistant tumors. These agents could represent a significant advance in the treatment of a wide variety of cancers."

Novel bisplatinum complexes characterized by an improved in vitro plasma protein binding and in vivo efficacy on xenograft models (Abstract A267)

Scientists from CTI-Europe presented data on two novel bis-platinum complexes, CT-47613 and CT-47609. When tested in animal models of ovarian cancer and colon cancer, the bis-platinates were significantly more potent than the two most commonly used platinum based chemotherapy drugs, carboplatin and cisplatin and oxaliplatin. Importantly these agents demonstrated potent anti-tumor activity in tumors with either acquired or intrinsic resistance to cisplatin or carboplatin, representing the first such class of binuclear platinum based
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...io,Nov.24/PRNewswire-FirstCall/--DowAgroSciencesCa...eds,adivisionofThompsonsLimitedofBlenheim,Ontario....iences,currentseedsbusinessasthecompanyanticipates...roSciencesHerbicideTolerantTraitTechnologyincornin...e. ,, "Thisacquisitionbringstogethertwostrongpr...
(Date:11/24/2009)...re-FirstCall/--Sigma-AldrichCorporation(Nasdaq: SI...day,December1stat1:45PMGMTinLondon,7:45AMUS/CST.In...heInternetavailableat http://inve s tor.sig m ...toaccessthisfile. ,, AboutSigma-Aldrich: Sig...mpany.Itschemicalandbiochemicalproductsandkitsareu...
(Date:11/24/2009)...er24/PRNewswire-FirstCall/--deCODE,genetics,Inc.(N...firstday"motionsbytheU.S.BankruptcyCourtfortheDist...ekfiledavoluntarypetitionfor,reliefunderChapter11o...urt. , TheordersissuedbytheBankruptcyCourtall...heChapter11proceedings.Inparticular,the,companyrec...
(Date:11/24/2009)...RNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ...ommercializingnovelpainmanagementtherapies,announc...veOfficer,isscheduledtopresentatthe21stAnnualPiper...09atTheNewYorkPalaceHotelinNewYork,NewYork. ,, ...r,willbeavailabletorespondtoquestionsduringthepres...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
...utics, Inc. (Nasdaq: NLTX ), today announced tha...s natriuretic peptide franchise, including CD-NP w...ilure, and CU-NP which is a pre-clinical compound....-99 and return license rights for the compound to ...that we are unable to continue to pursue the devel...
...wire-Asia-FirstCall/ -- China-Biotics, Inc.,(Nasda...ading Chinese firm,specializing in the manufacture...n of probiotics products, today announced the Stat...cturing certificates for the production of,several...iotics Gegen Capsules,Probiotics Tremella Polysacc...
...s Biotechnologies ( www.epeiusbiotech.com ) announ...ing the safety and efficacy of Rexin-G in chemothe...GI Symposium, #249; Sant P Chawla, P.I., Santa Mon... and there was no dose-limiting toxicity. At Dose ...th no tumor progression; and at Dose Level II, one...
Other Biology Technology:Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 2Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 3Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 4China-Biotics, Inc. Receives Manufacturing Certificate for New Products 2China-Biotics, Inc. Receives Manufacturing Certificate for New Products 3REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009) 2
(Date:11/23/2009)... - By producing some of the highest resolution ima...entists have a deeper understanding how biomolecul...ay lead to a new treatment for kidney stones using...the Nov. 23 online edition of the journal Proceed...s how peptides interact with mineral surfaces by a...
(Date:11/23/2009)...niversity of New Hampshire microbiologist Louis Ti...vance understanding of the actinorhizal plants, wi...rient-poor and contaminated soils. , The United...isa, a professor of molecular, cellular and biomed...elationship between the bacteria Frankia and Casua...
(Date:11/23/2009)...A string of recent discoveries about the multiple ...in this multi-purpose nutrient, increased awarenes...in it, spurred research and even led to an appreci...s ranging from the health of your immune system to...y to influenza, vitamin D is now seen as one of th...
Breaking Biology News(10 mins):Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3UNH prof. receives nearly $500,000 to research environmentally significant plants 2Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3The Hidden Story 3A Poetry Inspired by Authors Struggle with Depression Addiction 48573 1The Hidden Story 3A Poetry Inspired by Authors Struggle with Depression Addiction 48573 2Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo 28R 29 48570 1Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo 28R 29 48570 2Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo 28R 29 48570 3Transcept Pharmaceuticals Announces Expected FDA Extension of Regulatory Review Period for Intermezzo 28R 29 48570 4Industry Partners Step Up To Help Blood Cancer Patients 48567 1Industry Partners Step Up To Help Blood Cancer Patients 48567 2
...merican Society for Microbiology (ASM) will hold i...elphia, Pennsylvania. The meeting will feature app...ns spanning the breadth of microbiology and has an... study living organisms and infectious agents, and..., agriculture, the environment and biotechnology. ...
...GO - An experimental vaccine that triggers the pat...ic tumor cells is showing new promise for the trea...Rush University Medical Center are researching the...munotherapeutic, which is designed to kill cancer ... only five hospitals in Illinois offering the vacc...
... Processing and Mathematical Morphology: Fundament...reference book by NJIT computer science professor ... comprehensive overview of morphological mechanism...ssing. More than merely a tutorial on vital techni...to a theoretical framework. Morphology is the iden...
Other Biology News:Novel lung cancer vaccine shows promise in fighting early-stage lung cancer 2Image processing and mathematical morphology in new text by NJIT prof 2
...ultured in DMEM with 4 mM L-glutamine and harveste...e antigens in their native forms, cells were fixed...12-well (5 mm) adhesive coated slide, with each we...ar attachment and to minimize background staining....
Stains-All from Sigma-Aldrich
...p™ 10X PCR Enhancer (with betaine) substantia...ensitivity and specificity for amplification of ma...PCR eliminates the base-pair composition dependenc...lity, suppresses pauses of DNA polymerase, and red...
...with 96- or 384-well PCR plates Dimples on both s...n 96-tube plates End tabs on Thermo-Mat™ 384...ent sealing is achieved with either Thermo-Mat...r clip-down hot lid thermal cyclers Fully autocla...
Biology Products: